ID

15398

Description

Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02260414

Link

https://clinicaltrials.gov/show/NCT02260414

Keywords

Versions (1)
  1. 5/30/16 5/30/16 -
Uploaded on

May 30, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Lymphoma NCT02260414

English

Eligibility Lymphoma NCT02260414

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT02260414
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. body weight between 40 and 100 kg
Description

Body Weight

Data type

boolean

Alias
UMLS CUI [1]
C0005910
2. patient:
Description

Patient

Data type

boolean

Alias
UMLS CUI [1]
C0030705
2a- with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin (group 1) 2b- or hospitalized for aggressive lymphoma treated with chemotherapy (group 2) 2c- or older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac (group 3) decompensation
Description

Lymphoma stage | Indication Multiple Myeloma | Therapeutic procedure Thalidomide | Therapeutic procedure lenalidomide | Therapeutic procedure Erythropoietin | Hospitalization | Aggressive Non-Hodgkin Lymphoma | Chemotherapy Regimen | Age | Acute respiratory decompensation | Heart Decompensation

Data type

boolean

Alias
UMLS CUI [1]
C1272836
UMLS CUI [2,1]
C3146298
UMLS CUI [2,2]
C0026764
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0039736
UMLS CUI [4,1]
C0087111
UMLS CUI [4,2]
C1144149
UMLS CUI [5,1]
C0087111
UMLS CUI [5,2]
C0014822
UMLS CUI [6]
C0019993
UMLS CUI [7]
C1332225
UMLS CUI [8]
C0392920
UMLS CUI [9]
C0001779
UMLS CUI [10]
C0748352
UMLS CUI [11]
C1961112
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient requiring anticoagulant therapy at curative doses
Description

Anticoagulant therapy Curative

Data type

boolean

Alias
UMLS CUI [1,1]
C0150457
UMLS CUI [1,2]
C1880198
patients with a lower platelet count 80 g / l
Description

Decreased platelet count

Data type

boolean

Alias
UMLS CUI [1]
C0392386
subject with a history of heparin-induced thrombocytopenia
Description

Heparin-induced thrombocytopenia

Data type

boolean

Alias
UMLS CUI [1]
C0272285
subject with a history of hemorrhagic disease
Description

Hemorrhagic Disorders

Data type

boolean

Alias
UMLS CUI [1]
C0019087
history of severe trauma within 6 weeks prior to enrollment
Description

Trauma Severe

Data type

boolean

Alias
UMLS CUI [1,1]
C3714660
UMLS CUI [1,2]
C0205082
organic lesion at risk of bleeding
Description

Lesion Organ

Data type

boolean

Alias
UMLS CUI [1,1]
C0221198
UMLS CUI [1,2]
C0178784
poor renal with creatinine clearance <30 ml / min
Description

Abnormal renal function | Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1]
C0151746
UMLS CUI [2]
C0373595
hypersensitivity to tinzaparin
Description

Hypersensitivity tinzaparin

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0216278
events or bleeding tendencies associated with coagulation disorders
Description

Event Associated with Blood Coagulation Disorders | Bleeding tendency Associated with Blood Coagulation Disorders

Data type

boolean

Alias
UMLS CUI [1,1]
C0441471
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C0005779
UMLS CUI [2,1]
C1458140
UMLS CUI [2,2]
C0332281
UMLS CUI [2,3]
C0005779
subject on oral anticoagulant
Description

oral anticoagulants

Data type

boolean

Alias
UMLS CUI [1]
C0354604
for group 3: presence of hematological malignancy or active cancer
Description

Hematologic Neoplasms | Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1]
C0376545
UMLS CUI [2]
C0006826
Back to the top of the page

Similar models

Eligibility Lymphoma NCT02260414

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT02260414
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Body Weight
Item
1. body weight between 40 and 100 kg
boolean
C0005910 (UMLS CUI [1])
Patient
Item
2. patient:
boolean
C0030705 (UMLS CUI [1])
Lymphoma stage | Indication Multiple Myeloma | Therapeutic procedure Thalidomide | Therapeutic procedure lenalidomide | Therapeutic procedure Erythropoietin | Hospitalization | Aggressive Non-Hodgkin Lymphoma | Chemotherapy Regimen | Age | Acute respiratory decompensation | Heart Decompensation
Item
2a- with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin (group 1) 2b- or hospitalized for aggressive lymphoma treated with chemotherapy (group 2) 2c- or older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac (group 3) decompensation
boolean
C1272836 (UMLS CUI [1])
C3146298 (UMLS CUI [2,1])
C0026764 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0039736 (UMLS CUI [3,2])
C0087111 (UMLS CUI [4,1])
C1144149 (UMLS CUI [4,2])
C0087111 (UMLS CUI [5,1])
C0014822 (UMLS CUI [5,2])
C0019993 (UMLS CUI [6])
C1332225 (UMLS CUI [7])
C0392920 (UMLS CUI [8])
C0001779 (UMLS CUI [9])
C0748352 (UMLS CUI [10])
C1961112 (UMLS CUI [11])
Item Group
C0680251 (UMLS CUI)
Anticoagulant therapy Curative
Item
patient requiring anticoagulant therapy at curative doses
boolean
C0150457 (UMLS CUI [1,1])
C1880198 (UMLS CUI [1,2])
Decreased platelet count
Item
patients with a lower platelet count 80 g / l
boolean
C0392386 (UMLS CUI [1])
Heparin-induced thrombocytopenia
Item
subject with a history of heparin-induced thrombocytopenia
boolean
C0272285 (UMLS CUI [1])
Hemorrhagic Disorders
Item
subject with a history of hemorrhagic disease
boolean
C0019087 (UMLS CUI [1])
Trauma Severe
Item
history of severe trauma within 6 weeks prior to enrollment
boolean
C3714660 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Lesion Organ
Item
organic lesion at risk of bleeding
boolean
C0221198 (UMLS CUI [1,1])
C0178784 (UMLS CUI [1,2])
Abnormal renal function | Creatinine clearance measurement
Item
poor renal with creatinine clearance <30 ml / min
boolean
C0151746 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
Hypersensitivity tinzaparin
Item
hypersensitivity to tinzaparin
boolean
C0020517 (UMLS CUI [1,1])
C0216278 (UMLS CUI [1,2])
Event Associated with Blood Coagulation Disorders | Bleeding tendency Associated with Blood Coagulation Disorders
Item
events or bleeding tendencies associated with coagulation disorders
boolean
C0441471 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0005779 (UMLS CUI [1,3])
C1458140 (UMLS CUI [2,1])
C0332281 (UMLS CUI [2,2])
C0005779 (UMLS CUI [2,3])
oral anticoagulants
Item
subject on oral anticoagulant
boolean
C0354604 (UMLS CUI [1])
Hematologic Neoplasms | Malignant Neoplasms
Item
for group 3: presence of hematological malignancy or active cancer
boolean
C0376545 (UMLS CUI [1])
C0006826 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial